JM

Cascade BioSciences Inc.

TSX: CSBX

Mid-cap oncology developer. Lead candidate CSB-204 in Phase II. Disclosure quality has deteriorated across the last two reporting cycles.

OverviewFlagsFilingsContradictionsRisksNetworkEnforcementInsider trades

All filings

5 documents

FiledTypeTitleSEDAR+ ID
Apr 30, 2026MD&AManagement's Discussion & Analysis — Q1 2026SP-2026-04-30-CSBX-MDA-12290
Mar 28, 2025MD&AManagement's Discussion & Analysis — Year ended December 31, 2024SP-2025-03-28-CSBX-MDA-12044
Mar 28, 2025Annual Financial StatementsAudited Annual Financial Statements — Year ended December 31, 2024SP-2025-03-28-CSBX-AFS-12045
Feb 04, 2025News ReleaseCascade BioSciences Reports Positive CSB-204 Phase II Interim DataSP-2025-02-04-CSBX-NR-12031
Mar 30, 2024MD&AManagement's Discussion & Analysis — Year ended December 31, 2023SP-2024-03-30-CSBX-MDA-11842

Filing calendar

TypeDueFiledStatus
Annual Financial StatementsMar 31, 2025Mar 28, 2025on_time
MD&AMar 31, 2025Mar 28, 2025on_time
Interim Financial StatementsMay 15, 2026Apr 30, 2026on_time